# A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

> **NCT06431763** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 402 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran sodium
- **DRUG:** BPA

## Key facts

- **NCT ID:** NCT06431763
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-21
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-01-02
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431763, "A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06431763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*